Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial
Research article
[키워드] 95% CI
adverse event
adverse events
AEs
AEsAdverse events
anti-S IgG
anti-SARS-CoV-2 antibody
binding
Citadel
clinical development
Clinical research
collected
Concentration
conducted
COVID-19
COVID-19 vaccine
dose
Dose escalation
earth
effective
ELISA
enrolled
enrolment
EudraCT
facility
finding
Follow-up
force
funding
gene of Interest
geometric mean
GOIgene of Interest
healthy individual
Humoral response
IgG ELISA
immunoblot
immunogenic
induce
injection
interval
intramuscular
Joseph
Lipid
Lipid nanoparticle
LNP
LNPlipid nanoparticle
London
low dose
low dose vaccine
Medical Research Council
neutralisation
neutralisation assays
non-structural protein
NSPnon-structural protein
Open-label
participant
partner
Phase I
post-hoc
raised
ranged
required
RNA
RNA vaccine
Safe
Safety
saRNAself-amplifying RNA
SARS-CoV-2
self-amplifying RNA
sera
Serious Adverse Event
Seroconversion
serological evidence
Trial
Trust
vaccination
Vaccine
VEEVVenezuelan equine encephalitis virus
Venezuelan equine encephalitis virus
was measured
was related
wild type
[DOI] 10.1016/j.eclinm.2021.101262 [Article Type] Research article
[DOI] 10.1016/j.eclinm.2021.101262 [Article Type] Research article